Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HIL-214
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HilleVax’s Norovirus Vaccine Fails Phase 2 Trial, Stock Falls 80%
Details : HIL-214, an investigational IM vaccine for norovirus-related gastroenteritis, did not meet its primary endpoint in the NEST-IN1 trial. The company will stop its development in infants aged 5 months.
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : HIL-214
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : J.P. Morgan
Deal Size : $115.0 million
Deal Type : Public Offering
Details : HilleVax intends to use the net proceeds from the offering to fund the clinical development of HIL-214, a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by noro...
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : J.P. Morgan
Deal Size : $115.0 million
Deal Type : Public Offering
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
HilleVax Announces Pricing of Public Offering of Common Stock
Details : HilleVax intends to use the net proceeds from the offering to fund the clinical development of HIL-214, a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus ...
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $100.0 million
Deal Type : Public Offering
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HIL-214, its investigational virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe norovirus-related acute gastroenteritis (AGE) in infants.
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of the trial is to evaluate the protective efficacy of HIL-214 against the first confirmed moderate or severe AGE event due to a HIL-214 vaccine strain, GI.1 or GII.4, that occurs prior to each subject reaching 12 months of age.
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HIL-214 is bivalent vaccine candidate in development for prevention of AGE caused by norovirus infection, consists of virus-like particles which are designed to mimic structure of two major genotypes of norovirus, GI.1 and GII.4, and is co-formulated wit...
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HIL-214 is a VLP based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral acute gastroenteritis (AGE) worldwide.
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Frazier Healthcare
Deal Size : $135.0 million
Deal Type : Financing
Details : The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Product Name : HIL-214
Product Type : Vaccine
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : HIL-214
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Frazier Healthcare
Deal Size : $135.0 million
Deal Type : Financing